目的 探討胃康膠囊聯(lián)合泮托拉唑鈉腸溶膠囊治療消化性潰瘍的臨床療效。方法 選取2019年5月—2020年10月在南陽市中心醫(yī)院就診的106例消化性潰瘍患者，按照隨機數(shù)字表法將所有患者分為對照組和治療組，各有53例。對照組口服泮托拉唑腸溶膠囊，40 mg/次，1次/d。治療組在對照組治療的基礎(chǔ)上口服胃康膠囊，1.2 g/次，3次/d。兩組患者連續(xù)治療6周。觀察兩組的臨床療效，采用視覺模擬評分法（VAS）對患者主觀腹痛程度進行評估，檢測兩組治療前后血清白細胞介素-17（IL-17）、白細胞介素-1β（IL-1β）、基質(zhì)金屬蛋白酶-9（MMP-9）、表皮生長因子（EGF）、血管內(nèi)皮生長因子（VEGF）、轉(zhuǎn)化生長因子-α（TGF-α）水平。結(jié)果 治療后，治療組的總有效率為94.34%，對照組總有效率為81.13%，組間對比有顯著性意義（P<0.05）。治療后，兩組VAS評分顯著降低（P<0.05），以治療組VAS評分降低的更明顯（P<0.05）。治療后，兩組的IL-17、IL-1β、MMP-9水平顯著降低（P<0.05）；治療組的IL-17、IL-1β、MMP-9水平低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的EGF、VEGF、TGF-α水平顯著升高（P<0.05），以治療組EGF、VEGF、TGF-α水平升高的更明顯（P<0.05）。結(jié)論 胃康膠囊聯(lián)合泮托拉唑鈉腸溶膠囊可提高消化性潰瘍的臨床療效，減輕患者腹痛程度，降低炎癥因子，促進潰瘍面愈合，且安全性良好。

Objective To investigate the clinical efficacy of Weikang Capsules combined with Pantoprazole Sodium Enteric Capsules in treatment of peptic ulcer. Methods Patients (106 cases) with peptic ulcer in Nanyang Central Hospital from May 2019 to October 2020 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Pantoprazole Sodium Enteric Capsules, 40 mg/time, once daily. Patients in the treatment group were po administered with Weikang Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and the curative effect of two groups was observed, the degree of subjective abdominal pain was evaluated by VAS, and the serum levels of IL-17, IL-1β, MMP-9, EGF, VEGF, and TGF-α were detected before and after treatment. Results After treatment, the total effective rates in the treatment group and control group were 94.34% and 81.13%, with significant difference between the two groups (P<0.05). After treatment, the VAS score of two groups were significantly decreased (P<0.05), and the VAS score of the treatment group was significantly lower than that of the control group (P<0.05). After treatment, the levels of IL-17, IL-1β, and MMP-9 in two groups were significantly decreased (P<0.05); and the levels of IL-17, IL-1β, and MMP-9 in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of EGF, VEGF, and TGF-α in two groups were significantly increased (P<0.05), and the levels of EGF, VEGF, and TGF-α in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Weikang Capsules combined with Pantoprazole Sodium Enteric Capsules can improve the curative effect of peptic ulcer, reduce the degree of abdominal pain, reduce inflammatory factors, and promote ulcer healing, with good safety.

R975

河南省科技發(fā)展計劃項目（192102310326）